Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease

American Journal of Medicine

Volumn 105, Issue 6, 1998, Pages 494-499

  Harpaz, David ^a   Gottlieb, Shmuel ^b   Graff, Eran ^b   Boyko, Valentina ^b   Kishon, Yehezkiel ^a   Behar, Solomon ^b  

^a WOLFSON MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; CLINICAL OBSERVATION; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; RISK MANAGEMENT; SURVIVAL;

AGED; ASPIRIN; CEREBROVASCULAR DISORDERS; CONFOUNDING FACTORS (EPIDEMIOLOGY); CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK; VASODILATOR AGENTS;

EID: 0032411526     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00328-3     Document Type: Article

References (30)

1. 1. Aspirin Myocardial Infarction Study Research Group. A randomized controlled trial of aspirin in persons recovered from myocardial infarction. JAMA. 1980;243:661-669.
2. 2. Ridker PM, Manson JE, Gazizno JM, Buring JE, Hennekens CH. Low dose aspirin therapy for chronic stable angina: A randomized, placebo-controlled clinical trial. Ann Intern Med. 1991;114:835-839.
3. 3. SAPAT (Swedish Angina Pectoris Aspirin Trial) Group, Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R. Double blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992;340:1421-1425.
4. 4. Antiplatelet Trialist's Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
5. 5. Goldstein RE, Andrews M, Jackson Hall W, Moss AJ. Marked reduction in long-term cardiac deaths with aspirin after a coronary event. J Am Coll Cardiol. 1996;28:326-330.
6. 6. Harpaz D, Benderly M, Goldbourt U, Kishon Y, Behar S, for the Israeli BIP Study Group. Effect of aspirin on mortality in women with symptomatic or silent myocardial ischemia. Am J Cardiol. 1996;78:1215-1219.
7. 7. Behar S, Boyko V, Reicher-Reiss H, Goldbourt U. Ten-year survival after acute myocardial infarction: comparison of patients with and without diabetes. Am Heart J. 1997;133:290-296.
8. 8. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for coronary artery disease: the Framingham Study. Diabetes Care. 1979;2:120-126.
9. 9. Betteridge DJ, Zahavi J, Jones NAG, Shine B, Bakkar W, Galton DS. Platelet function in diabetes in relation to complications, glycosylated hemoglobin and serum lipoproteins. Eur J Clin Invest. 1981; 111:272-277.
10. 10. Lee H, Paton CR, Passa P, Caen JP. Fibrinogen binding and ADP-induced aggregation in platelets from diabetic subjects. Thromb Res. 1981;24:143-150.
11. 11. Mustard JF, Packham MA. Platelets and diabetes mellitus. NEJM. 1984;311:665-667.
12. 12. Di Minno G, Silver MJ, Cerbone AM, Riccardi G, Rivellese A, Mancini M, Thiagarjan P. Increased binding of fibrinogen to platelets in diabetes: the role of prostaglandins and thromboxane. Blood. 1985; 65:156-162.
13. 13. DiMinno G, Silver MJ, Cerbone AM, Riccardi G, Rivellese A, Mancini M. Platelet fibrinogen binding in diabetes mellitus: differences between binding to platelets from nonretinopathic and retinopathic diabetic patients. Diabetes. 1986;35:182-185.
14. 14. Hendra T, Betteridge DJ. Platelet function, platelet prostanoids and vascular prostacyclin in diabetes mellitus. Prostagland Leukotr Essent Fatty Acids. 1989;35:197-212.
15. 15. Mori TA, Vandongen R, Douglas AJ, McCulloch RK, Burke V. Differential effect of aspirin on platelet aggregation in IDDM: differences between binding to platelets from nonretinopathic and retinopathic diabetic patients. Diabetes. 1992;41:261-266.
16. 16. Colwell JA, Bingham SF, Abraira C, et al, and the Cooperative Study Group. Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Diabetic Care. 1986;9:140-148.
17. 17. Sivenius J, Laakso M, Riekkinen P Sr, Smet S, Lowenthal A. European Stroke Prevention Study: effectiveness of antiplatelet therapy in diabetic patients in secondary prevention of stroke. Stroke. 1992; 23:851-854.
18. 18. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: early treatment diabetic retinopathy study report 14. JAMA. 1992;268:1292-1300.
19. 19. Goldbourt U, Behar S, Reicher-Reiss H, et al, for the Bezafibrate Infarction Prevention Study Group. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol. 1993;71:909-915.
20. 20. SAS Institute Inc., SAS Technical Report P-229, SAS/STAT Software: Changes and enhancements release 6.07, Cary, NC: SAS Institute, 1992:433-480.
21. 21. Sagel J, Calwell JA, Crook L, Laimins M. Increased platelet aggregation in early diabetes mellitus. Ann Intern Med. 1975;82:735-738.
22. 22. Halushka PV, Lurie D, Colwell JA. Increased synthesis of prostaglandin-E-like material by platelets from patients with diabetes mellitus. NEJM. 1977;297:1306-1310.
23. 23. Halushka PV, Rogers RC, Loadholdt CB, Colwell JA. Increased platelet thromboxane synthesis in diabetes mellitus. J Lab Clin Med. 1981;97:87-96.
24. 24. Davi G, Catalano I, Averna M, et al. Increased thromboxane biosynthesis and platelet function in type II diabetes mellitus. NEJM. 1990;322:1769-1774.
25. 25. Davi G, Gresele P, Violi F, et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation. 1997;96: 69-75.
26. 26. FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased probiosynthesis in patients with severe atherosclerosis and platelet activation. NEJM. 1984;310:1065-1068.
27. 27. DiMinno G, Silver MI, Cerbone AM, Murphy S. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood. 1986;68:886-891.
28. 28. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;ii:349-360.
29. 29. The BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 1997;96:1761-1769.
30. 30. Ellis SG, Narins GR. Problem of angioplasty in diabetics. Circulation. 1997;96:1707-1710.